1 Title: High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and 2 cellular responses 3 Sulaimon Akanmu,<sup>1\*</sup> Bobby Brooke Herrera,<sup>2,3,4,5\*</sup> Beth Chaplin,<sup>2</sup> Sade 4 Authors: 5 Ogunsola,<sup>1</sup> Akin Osibogun,<sup>1,6</sup> Fatima Onawoga,<sup>1</sup> Sarah John-Olabode,<sup>1</sup> Iorhen E. Akase,<sup>1</sup> Augustina Nwosu,<sup>1</sup> Donald J Hamel,<sup>2</sup> Charlotte A Chang,<sup>2</sup> Phyllis J Kanki<sup>2</sup> 6 7 8 \*Co-first author 9 10 Affiliations: <sup>1</sup>Lagos University Teaching Hospital, College of Medicine, University of Lagos, Lagos, 11 12 Nigeria 13 <sup>2</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public 14 Health, Boston, MA, USA 15 <sup>3</sup>Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases, and 16 Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, 17 Rutgers University, New Brunswick, NJ, USA <sup>4</sup>Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA 18 19 <sup>5</sup>Mir Biosciences, Inc., Boston, MA, USA 20 <sup>6</sup>Lagos State COVID-19 Taskforce, Lagos State Ministry of Health, Lagos, Nigeria 21 22 Correspondence: PK, pkanki@hsph.harvard.edu 23

## 24 Abstract:

### 25 Background

Early evidence suggested that the impact of the COVID-19 pandemic was less severe in Africa compared to other parts of the world. However, more recent studies indicate higher SARS-CoV-2 infection and COVID-19 mortality rates on the continent than previously documented. Research is needed to better understand SARS-CoV-2 seroprevalence and immunity in Africa.

#### 31 <u>Methods</u>

Our collaboration with the Lagos State COVID-19 Taskforce, enabled secondary analyses of immune responses in healthcare workers (HCWs) and Oxford/AstraZeneca COVID-19 vaccine recipients from the general population across 5 local government areas (LGAs) in Lagos State, Nigeria. Western blots were used to simultaneously detect SARS-CoV-2 spike and nucleocapsid (N) antibodies and stimulation of peripheral blood mononuclear cells with N followed by an IFN-γ ELISA was used to examine T cell responses.

39 Findings

Antibody data demonstrated high SARS-CoV-2 seroprevalence of 71.6% (96/134)
in HCWs and 54.8% (63/115) in the general population. Antibodies directed to only
SARS-CoV-2 N, suggesting pre-existing coronavirus immunity, were seen in 10.4%
(14/134) of HCWs and 20.0% (23/115) of the general population. T cell data showed that
IFN-γ responses against SARS-CoV-2 N were robust in detecting exposure to the virus,
demonstrating 87.5% sensitivity and 92.3% specificity.

46 Interpretation

47	These results have important implications for understanding the paradoxical high
48	SARS-CoV-2 infection with low mortality rate in Africa as compared to other parts of the
49	world, as well as for the development of T cell-based diagnostics and vaccines.
50	
51	Funding
52	Harvard University, Motsepe Presidential Research Accelerator Fund for Africa
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	

# 70 Introduction:

71

72 Early projections of SARS-CoV-2 spread in Africa fueled fears that the healthcare 73 infrastructure on the continent would be ill prepared to cope with the anticipated COVID-74 19 hospitalizations and deaths (1). However, as of October 2022, 12.1 million COVID-19 75 cases and 256,000 deaths have been reported in Africa, representing ~2% and ~4% of 76 global statistics, respectively. Early studies indicated a less severe epidemiological 77 picture of COVID-19 in Africa, with a higher proportion of cases resulting in asymptomatic 78 infections and lower mortality compared to other parts of the world (2). Several factors 79 may help explain these phenomena including the younger age demographics with 80 stronger immune status, climate and environmental factors, and weak health systems for 81 reporting (3-5).

82 In Africa, SARS-CoV-2 prevalence studies conducted in blood donors, healthcare workers (HCWs), pregnant women, and others have described varying rates during 83 84 different time periods, ranging from 0.4% in Cape Verde (June-July 2020) to more than 49% in Kenya (August 2020-October 2021) and 79% across 12 states in Nigeria (June-85 86 August 2021) (6-8). In most cases, the reported prevalence of antibodies against SARS-87 CoV-2 was several orders of magnitude higher than would be expected from PCR 88 confirmed cases. However, more recent evidence indicates an underestimation of 89 COVID-19's impact in Africa. In Zambia, postmortem surveillance conducted between 90 June 15 and October 1, 2020, detected SARS-CoV-2 RNA in ~20% of subjects sampled 91 within 48 hours of death, and only 2 of the 70 had been diagnosed with SARS-CoV-2 92 prior to death (9). A follow-up study showed that during peak transmission periods,

approximately 90% of all deceased individuals tested positive for COVID-19 (10). While
these studies demonstrate under-reporting of SARS-CoV-2 infection, there remains a lack
of evidence for major increases in mortality, at least suggestive of lower pathogenic
impact.

97 The humoral response to SARS-CoV-2 has been the primary focus of most studies 98 conducted in Africa. A study of pre-pandemic samples in Gabon and Senegal, 99 demonstrated significant pre-existing immunity based on antibodies directed to the 100 SARS-CoV-2 spike (S) and nucleocapsid (N) proteins, in contrast to samples from 101 Canada, Brazil and Denmark (11). However, Gabonese sera with or without antibodies 102 to SARS-CoV-2 N were unable to neutralize the virus in vitro or in mouse infection studies. 103 These data, along with other published studies confirm pre-existing humoral responses 104 to SARS-CoV-2 that may be gualitatively and guantitatively distinct in Africa.

105 The study of T cell responses has also been used in research and clinical settings 106 during the COVID-19 pandemic to provide further insights into the immune response to 107 infection and/or vaccination. In contrast to humoral responses, T cell responses to human 108 coronaviruses, including SARS-CoV-1 and SARS-CoV-2, may be long-lasting even many 109 years after infection (12, 13). SARS-CoV-2-specific T cells were maintained at 6-9 months 110 following primary infection, indicating that T cell immunity may persist beyond antibody 111 responses (12). Preclinical development of SARS-CoV-2 vaccines have demonstrated T 112 cell responses accompanying antibody responses and clinical studies are now 113 demonstrating similar timelines following vaccination (14). These findings, together with 114 studies that have demonstrated a role for T cells in viral clearance, suggest that cell-115 mediated immune responses may be an important component of protection against

116 SARS-CoV-2 (15). Here we report the results of antibody and T cell analyses using 117 Nigerian samples from HCWs and a group of vaccine recipients from the general 118 population prospectively followed post-vaccination. To our knowledge, this is the first 119 study to examine both the antibody and T cell response to SARS-CoV-2 in West Africans. 120 121 Methods: 122 123 Study Population and Ethics Statement 124 125 Our original study in early 2021 proposed to only recruit HCWs, a population with 126 high-risk occupational exposure to COVID-19. However, the roll-out of COVID-19 127 vaccines in Nigeria at the end of March 2021 enabled study of vaccine recipients from 128 communities also from Lagos state. The Oxford AstraZeneca vaccine, with its low cost 129 and simple refrigeration requirements enabled equitable access for low- and middle-130 income countries and was the first non-profit vaccine to report efficacy. The 131 recommended initial course is two doses, administered intramuscularly with an interval of 132 8–12 weeks between doses.

133 The HCW cohort was recruited from the Lagos University Teaching Hospital 134 (LUTH). Study participation included a brief clinical examination, questionnaire and 135 venous blood sample. HCWs included some with documented prior COVID-19 infection 136 by PCR. HCW samples were collected between March and October 2021.

137The Lagos State Vaccine study population included individuals from the general138population from Agbowa, Amuwo, Ikorodu, Iwaya, and Oshodi, Lagos State, Nigeria, all

of whom, at the time of enrollment, had no documented history of SARS-CoV-2 infection and were administered the first dose of the Oxford/AstraZeneca COVID-19 vaccine between March to June 2021. A brief questionnaire on demographics and exposure was administered at baseline, and venous blood samples were collected at baseline (immediately before vaccination), 7-, 14-, and 84-days after vaccination for immune response testing.

145 All individuals from each of the 2 cohorts provided written informed consent for the 146 collection of samples and data. The HCW study received ethical clearance from the 147 Harvard T.H. Chan School of Public Health Institutional Review Board (IRB, Protocol #: 148 IRB-21-0329) and the LUTH Health Research Ethics Committee (HREC, Protocol #: 149 ADM/DCST/HREC/APP/4192). The original Lagos State COVID-19 Vaccine study was 150 reviewed and approved by the LUTH HREC (Protocol #: ADM/DCST/HREC/APP/4207), 151 and the secondary analysis of these samples was determined not human subjects 152 research by the Harvard IRB (Protocol #: IRB21-1350).

153

154 Viral Lysate

155

Briefly, Vero cells infected with SARS-CoV-2 (Isolate USA-WA1/2020, BEI Resources NR-52281) were lysed when cytopathic effect were observed in 20% of cells with lysis buffer containing protease inhibitors, followed by centrifugation at 170,000 x g at 4°C for 90 minutes to obtain cell lysates. Aliquots of cell lysates were purified by sucrose gradient.

161

## 162 Western Blot

163

164	Aliquots of cell lysates were added to nonreducing buffer (final concentrations of		
165	2% SDS, 0.5 M Tris pH 6.8, 20% glycerol, 0.001% bromophenol blue) and subjected to		
166	12% PAGE and Western blot analysis using patient serum (1:250) as primary antibody		
167	and anti-human IgG horseradish peroxidase (HRP) (1:2,000; ThermoFisher Scientific,		
168	Waltham, MA) as secondary antibody. Visualization was performed using Metal		
169	Enhanced DAB Substrate Kit (ThermoFisher Scientific, Waltham, MA) per the		
170	manufacturer's instructions.		
171			
172	Image analysis		
173			
174	Western blots were analyzed using image processing software, ImageJ (NIH), to		
175	machine-read and quantify SARS-CoV-2 S antibody signals. The average pixel intensity		
176	was quantified at the Western blot SARS-CoV-2 S band, background areas, and a control		
177	band. The background-adjusted SARS-CoV-2 S band signal was then normalized to the		
178	background-subtracted control band and expressed as % of control.		
179			
180	T cell stimulation		
181			
182	From each individual, 3 ml whole blood was collected in a vacutainer tube treated		
183	with lithium or sodium heparin (BD, Franklin Lakes, NJ), and tubes were inverted 10 times		

to ensure that the blood mixed thoroughly with the anticoagulant. 1 ml whole blood was

185 then pipetted into three MASI Stimulator Tubes (Mir Biosciences, Boston, MA) either 186 coated with SARS-CoV-2 N, positive control (phytohemagglutinin), or negative control 187 (PBS). All tubes were then inverted 25 times to ensure that the whole blood mixed 188 thoroughly along the inner walls of the MASI Stimulator Tubes. The MASI Stimulator 189 Tubes were incubated in a humidified incubator at 37°C with 5% CO<sub>2</sub> for 18-22 hours. 190 After the incubation step, the MASI Stimulator Tubes were centrifuged at 2,500 x g for 5 191 minutes and the supernatant was aliquoted into 1 ml cryotubes and immediately 192 processed by the IFN-y ELISA.

193

194 IFN-γ ELISA

195

Supernatants (100  $\mu$ I) collected from the MASI Stimulator Tubes were screened for the presence of human IFN- $\gamma$  by the MASI-COVID enzyme-linked immunosorbent assay (ELISA) (Mir Biosciences, Boston, MA), according to the manufacturer's instructions. The presence of IFN- $\gamma$  was captured using a microplate reader (optical density 450 nm). Assay performances were monitored using internal controls and cutoffs were determined as specified by the manufacturer for the kit.

202

203 Statistics

204For both the HCW and general population vaccine recipient cohorts, we calculated205baseline SARS-CoV-2 S and N antibody seroprevalence determined by Western blot as206percentage of total. Using these seroprevalence categories, we evaluated T cell207responses after stimulation with SARS-CoV-2 N by plotting IFN-γ ELISA signal in a subset

208 of HCW baseline samples and 7-day post-vaccination general population samples. 209 Additionally, for the vaccine recipient cohort, we used the Western blot and image 210 analysis to evaluate boosting of SARS-CoV-2 S antibodies in sequential samples post-211 vaccination by calculating mean S signal and change over time. The mean S antibody 212 signal between groups was compared by T-test. Finally, we calculated sensitivity and 213 specificity of IFN-y responses against SARS-CoV-2 N. All statistics and plots were 214 generated using Prism (version 9.0.0). 215 216 Role of the funding source 217 218 Authors declare that the funder did not have any role in the study design; in the 219 collection, analysis, and interpretation of data; in the writing of the report; and in the 220 decision to submit the paper for publication. 221 222 **Results:** 223 224 Our study included a cohort of 134 HCWs working at LUTH. Forty HCWs 225 previously tested positive for COVID-19 by RT-PCR and 94 did not have history of 226 documented SARS-CoV-2 infection. (Table 1). Our study also included a second cohort 227 of 126 individuals from the general population across 5 local government areas of Lagos 228 State: 25 from Agbowa, 26 from Amuwo, 25 from Ikorodu, 25 from Iwaya, and 25 from 229 Oshodi (Table 1). At the time of enrollment, referred to throughout as baseline, a blood 230 sample was collected from each individual, immediately prior to administration of the first

dose of the Oxford/AstraZeneca COVID-19 vaccine. For these individuals, baseline and
 follow-up samples were collected between March and August 2021.

233 We analyzed the SARS-CoV-2 seroprevalence based on antibodies directed 234 against SARS-CoV-2 S+N or S-only. The overall seroprevalence of SARS-CoV-2 in 235 HCWs was 71.6% (96/134) (Table 1). Of HCWs with previous RT-PCR confirmation of 236 COVID-19, 100% (40/40) had SARS-CoV-2 S+N or S-only antibodies (Table 1). Of HCWs 237 without any prior history, 58.5% (55/94) had SARS-CoV-2 S+N antibodies, whereas 1.1% 238 (1/94) had S-only antibodies (Table 1). We then examined the T cell response against 239 SARS-CoV-2 N. In HCWs with SARS-CoV-2 S+N antibodies, 82.6% (19/23) had a T cell 240 response against N (Fig. 1A).

We next examined HCWs with antibodies directed against SARS-CoV-2 N-only, suggestive of pre-existing coronavirus immunity. There was reactivity to N-only in 10.4% (14/134) of HCWs, all with no history of PCR-confirmed SARS-CoV-2 infection (Table 1). Of those we tested for T cell responses, 100% (1/1) had a T cell response against SARS-CoV-2 N (Fig. 1B). Additionally, 17.9% (24/134) of HCWs were seronegative to SARS-CoV-2. Of those we tested, 75% (6/8) did not have a T cell response against SARS-CoV-2 N (Table 1, Fig. 1C).

We similarly analyzed the SARS-CoV-2 antibody profiles in the general population vaccine recipients. At baseline, the overall SARS-CoV-2 seroprevalence was 54.8% (63/115), with reactivity to SARS-CoV-2 N-only in 20% (23/115), suggestive of preexisting coronavirus immunity (Table 1). 25.2% of the general population vaccine recipients were seronegative (29/115). Across the five local government areas, SARS-CoV-2 seroprevalence ranged from 34.8% in Amuwo to 66.7% in Ikorodu. The reactivity

to SARS CoV-2 N-only was more consistent across the local government areas, ranging
from 16.7% in Ikorodu to 22.7% in Oshodi (Table 1).

256 Given that the Oxford/AstraZeneca COVID-19 vaccine is designed to generate 257 immunity against the SARS-CoV-2 S, we next examined the evolution of SARS-CoV-2 S 258 antibodies post-vaccination. Most individuals, regardless of their SARS-CoV-2 antibody 259 status at baseline, had detectable S antibodies post-vaccination (Fig. 2A-E). However, 260 the potency of the SARS-CoV-2 S antibody response differed between baseline antibody profile groups. The S antibody response was significantly stronger in individuals with 261 262 baseline SARS-CoV-2 S+N antibodies compared to those with N-only antibodies or 263 seronegatives at 7- (p < 0.0001 or p < 0.0003, respectively) and 14-days (p < 0.002 or p 264 < 0.02, respectively) post-vaccination (Fig. 2F). For the SARS-CoV-2 S+N baseline 265 group, the S antibody response remained significantly stronger only compared to the 266 seronegative group at 84-days post-vaccination (p < 0.03) (Fig. 2F). The SARS-CoV-2 S-267 only baseline group had a significantly stronger S antibody response compared to the N-268 only baseline group only at 7-days post-vaccination (p < 0.005) (Fig. 2F). The SARS-269 CoV-2 N-only baseline group had a significantly stronger S antibody response compared 270 to the seronegative baseline group only at 84-days post-vaccination (p < 0.004) (Fig. 2F). 271 Also, 6 of 115 individuals (5.2%), all of whom were seronegative at baseline, failed to 272 develop SARS-CoV-2 S antibodies 4 weeks after the second vaccine dose (Fig. 2D-E).

Since some individuals already had SARS-CoV-2 S antibodies at baseline, suggesting prior SARS CoV-2 infection, we also examined the levels of S boosting postvaccination. In individuals with SARS-CoV-2 S+N antibodies at baseline, 74.4% of S boosting occurred within 7-days post vaccination, followed by 24.5% and 1.2% within 14-

and 84-days post-vaccination, respectively (Fig. 3). For individuals with S-only antibodies or were seronegative at baseline, ~36.6% of S boosting occurred within 7-days postvaccination, followed by 56.4% and ~7% within 14- and 84-days post-vaccination, respectively (Fig. 3). S boosting in individuals with SARS-CoV-2 N-only antibodies at baseline differed compared to other groups, with relatively consistent levels between time periods. For these individuals, 22.9%, 39.9%, and 37.2% of S boosting occurred within 7-, 14-, and 84-days post-vaccination, respectively (Fig. 3).

We then examined the T cell response against SARS-CoV-2 N in individuals in the general population 7-days post-vaccination. In individuals with SARS-CoV-2 S+N antibodies, 55.9% (33/59) had a T cell response against SARS-CoV-2 N (Fig. 4A). In individuals with N-only antibodies 100% (2/2) had T cell responses against SARS-CoV-2 N, respectively (Fig. 4B). In individuals who were seronegative, 100% (18/18) did not have T cell responses against SARS-CoV-2 N (Fig. 4C).

Finally, we calculated the sensitivity and specificity to determine the efficacy of using T cell IFN-γ against SARS-CoV-2 N as a diagnostic biomarker for exposure. The positive control group consisted of 16 HCWs with previous RT-PCR confirmation of COVID-19 and the negative control group consisted of 26 HCWs and individuals in the general population who were seronegative. The resulting sensitivity was 87.5% and the specificity was 92.3% (Table 2).

296

297 **Discussion:** 

299 In Africa, the immunological response to SARS-CoV-2 and non-SARS 300 coronaviruses represents a critical research gap that may shed light on the paradoxical 301 high SARS-CoV-2 infection with low mortality rate as compared to other parts of the world. 302 The goal of the present study was to profile the antibody and T cell responses in natural 303 SARS-CoV-2 infection and COVID-19 vaccination in two Nigerian cohorts. There are four 304 important findings from our study. First, antibodies directed against SARS-CoV-2 S+N, 305 suggestive of previous exposure the virus, were observed in a majority of individuals prior 306 to vaccination. These results agree with other SARS-CoV-2 seroprevalence studies, 307 suggesting a very high infection rate by 2021. Second, having antibodies to SARS CoV-308 2 N-only is suggestive of pre-existing coronavirus immunity, as represented by HCWs 309 and the general population with N-only antibodies prior to vaccination. Third, SARS-CoV-310 2 S antibody boosting occurs more rapidly in individuals with prior SARS-CoV-2 infection. 311 Finally, T cell IFN-y against SARS-CoV-2 N is a robust method to detect exposure to the 312 virus as demonstrated by the high detection rate among the HCWs with prior PCR-313 confirmed COVID-19.

Studies have shown that the antibody response to natural infection by SARS-CoV-2 is highly variable (16). In some cases, individuals never produce a detectable antibody response, or low antibody titers have been observed in individuals with mild or asymptomatic infections (16, 17). The vast majority of antibody studies have utilized ELISA assays to recombinant SARS CoV-2 antigens. Multiple studies now indicate reduced specificity of these assays when analyzing samples originating from sub-Saharan Africa (11, 18). Of note, our study employed virion based immunoblot which

enabled simultaneous visualization of antibody responses to multiple SARS-CoV-2
 antigens with multiple positive and negative controls to ensure specificity.

Our antibody data showed a high SARS-CoV-2 seroprevalence in Nigeria with strong antibody reactivity. A majority of individuals, including 71.6% of HCWs and 54.8% of the general population vaccine recipients, had antibodies directed against SARS-CoV-2 S+N (Table 1). These data are in comparison to studies conducted in Nigeria between June and December 2020 showing lower seroprevalence rates ranging between 17-25% (19, 20).

329 While COVID-19 vaccines have also been shown to induce robust antibody 330 responses, there is strong evidence that these responses decline in the months following 331 the second or boosting doses (21, 22). Our data demonstrate that a majority of general 332 population vaccine recipients, regardless of baseline antibody status, developed SARS-333 CoV-2 S antibodies post-vaccination (Fig. 2). However, six individuals (5.2% across 334 vaccine population) failed to develop an antibody response even after two vaccine rounds 335 (Fig. 2D-E). Moreover, previous SARS-CoV-2 immunity appears to impact the level of S 336 antibody boosting. Vaccination with the Oxford/AstraZeneca COVID-19 vaccine boosted 337 74% of S antibodies within 7 days in individuals who already had SARS-CoV-2 S+N 338 antibodies at baseline (Fig. 3). In contrast, only 39%, 23%, or 34% of S boosting occurred 339 within 7 days in individuals who demonstrated S-only or N-only antibodies or were 340 seronegative at baseline, respectively (Fig. 3). Importantly, analysis was not performed 341 on samples beyond 84-days post-vaccination; therefore, we are unable to postulate on 342 antibody waning. However, several studies have demonstrated substantial antibody 343 waning after vaccination with the Oxford/AstraZeneca COVID-19 vaccine (23).

344 During infection with SARS-CoV-2, S and N proteins are major targets of both 345 antibodies and T cells (24). While SARS-CoV-2 S protein is more genetically diverse 346 among coronavirus infected humans and animals, the N protein is highly conserved (25). 347 Our antibody data suggests pre-existing coronavirus immunity with 10.4% (14/134) of 348 HCWs and 20% (23/115) of individuals in the general population who only had SARS-349 CoV-2 N antibodies prior to vaccination. These results recapitulate other studies 350 highlighting a similar phenomenon (11, 18, 26). SARS-CoV-2 N seropositivity could 351 suggest undocumented infections with other as yet unrecognized coronaviruses, 352 including animal coronaviruses. There is 93-100% homology between SARS-CoV-2 and 353 several bat and pangolin N proteins at the amino acid level, and both alpha and 354 betacoronaviruses have been isolated from animals in Central and West Africa (11, 27, 355 28). The dynamics of antibody waning post natural infection is not well studied. It is 356 possible that waning of S antibodies may result in the SARS-CoV-2 N antibody only 357 profile. Prospective serologic studies are needed in these populations to further elucidate 358 this finding.

359 We also report, for the first time, T cell responses against SARS-CoV-2 N in West 360 Africans. The T cell assay used in this study does not require peripheral blood 361 mononuclear cell (PBMC) isolation, offering ease-of-use and a more time-sensitive 362 procedure from sampling to result. Instead, an individual's whole blood is collected in 363 lithium heparin tubes, followed by T cell stimulation in the kit's specialized tubes coated 364 with SARS-CoV-2 N protein or positive/negative controls. After stimulation, supernatants 365 are processed via a one-step ELISA to measure IFN-y secreted by T cells that responded 366 to the SARS-CoV-2 N protein.

367 Evidence suggests that most individuals infected with SARS-CoV-2 generate IFN-368 y-producing T cells that can be detected in peripheral blood as early as 2-4 days from the 369 onset of symptoms or between 7-14 days after vaccination (29, 30). Our results 370 demonstrate a high sensitivity and specificity in detecting exposure to SARS-CoV-2 371 based on whole blood IFN-y. In HCWs with previous RT-PCR confirmation of COVID-19, 372 the sensitivity of T cell IFN-y against SARS-CoV-2 N was 87.5%. The specificity of the 373 assay in individuals who were seronegative was 92.3% (Table 2). In individuals from the 374 general population who were seronegative, none had detectable T cell IFN-y responses. 375 However, two HCWs who were seronegative had a positive T cell response. These may 376 have been false positives or the T cell response to SARS-CoV-2 N was skewed by pre-377 existing immunity to other pathogens including globally endemic human non-SARS 378 coronaviruses (25).

379 This study has limitations. Our study populations of HCWs and the general 380 population of vaccine recipients were relatively small. Second, while our results are 381 suggestive of pre-existing coronavirus immunity, it was not within the scope of the study 382 to confirm the specific coronavirus responsible for the response. Studies will be required 383 to determine whether pre-existing coronavirus immunity may alter susceptibility to SARS-384 CoV-2 infection and/or COVID-19 severity. Third, the focus of the T cell response was on 385 SARS-CoV-2 N. While we observed robust responses to N, there are other proteins that 386 have been shown to be targeted by T cells, which may correlate with disease severity. 387 Finally, due to the limited amount of blood collected for each patient, we were unable to 388 define the CD4- and CD8-specific T cell responses.

In conclusion, our study demonstrates high SARS-CoV-2 seroprevalence as well as possible preexisting coronavirus immunity in the Nigerian population in 2021, and also provides new data on T cell responses as well as antibody boosting after vaccination based on prior infection/exposure. Our findings highlight the need for further investigations to better understand the immune mechanisms and consequences related to pre-existing coronavirus immunity in West Africa. Pre-existing B cell and/or T cell memory may have important implications for natural infection and disease outcomes. Identification of conserved antibody and/or T cell epitopes may hold promise for improved vaccines protecting against current and future coronaviruses. 

#### 412 **References:**

413

Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Boelle PY, et al.
 Preparedness and vulnerability of African countries against importations of COVID-19: a
 modelling study. Lancet. 2020;395(10227):871-7.

417 2. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. Nat Rev
418 Immunol. 2021;21(8):469-70.

Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso
 A. Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and
 Seasonality of Coronavirus Disease 2019 (COVID-19). JAMA Netw Open.
 2020;3(6):e2011834.

423 4. Gaye B, Khoury S, Cene CW, Kingue S, N'Guetta R, Lassale C, et al. Socio-424 demographic and epidemiological consideration of Africa's COVID-19 response: what is 425 the possible pandemic course? Nat Med. 2020;26(7):996-9.

426 5. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et al.
427 What Could Explain the Lower COVID-19 Burden in Africa despite Considerable
428 Circulation of the SARS-CoV-2 Virus? Int J Environ Res Public Health. 2021;18(16).

Gomez LF, Mendes C, Silva JS, Semedo FH, Barreto JN, Monteiro Rodrigues J,
et al. Sero-epidemiological survey and profile of SARS-CoV-2 infection in Cape Verde.
Available at SSRN 3762489. 2021.

432 7. Lucinde R, Mugo D, Bottomley C, Aziza R, Gitonga J, Karanja H, et al. Sero433 surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral
434 hospitals. MedRxiv. 2021.

Kolawole OM, Tomori O, Agbonlahor D, Ekanem E, Bakare R, Abdulsalam N, et
al. SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in
Nigeria. JAMA Netw Open. 2022;5(10):e2236053.

438 9. Mwananyanda L, Gill CJ, MacLeod W, Kwenda G, Pieciak R, Mupila Z, et al.

Covid-19 deaths in Africa: prospective systematic postmortem surveillance study. BMJ.
2021;372:n334.

441 10. Gill CJ, Mwananyanda L, MacLeod W, Kwenda G, Pieciak R, Etter LE, et al.
442 Sustained high prevalence of COVID-19 deaths from a systematic post-mortem study in
443 Lusaka, Zambia: one year later. medRxiv. 2022.

Pedersen J, Koumakpayi IH, Babuadze G, Baz M, Ndiaye O, Faye O, et al. Crossreactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes
the COVID-19 pandemic. Sci Rep. 2022;12(1):12962.

447 12. Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS448 CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat
449 Immunol. 2021;22(5):620-6.

450 13. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-

451 CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

452 Nature. 2020;584(7821):457-62.

453 14. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2
454 vaccination induces immunological T cell memory able to cross-recognize variants from
455 Alpha to Omicron. Cell. 2022;185(5):847-59 e11.

Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. Early
induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance
and mild disease in COVID-19 patients. Cell Rep. 2021;34(6):108728.

459 16. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson
460 E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med.
461 2020;383(18):1724-34.

462 17. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et
463 al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus
464 severe COVID-19. J Allergy Clin Immunol. 2021;147(2):545-57 e9.

465 18. Emmerich P, Murawski C, Ehmen C, von Possel R, Pekarek N, Oestereich L, et
466 al. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum
467 samples of African origin. Trop Med Int Health. 2021;26(6):621-31.

Majiya H, Aliyu-Paiko M, Balogu VT, Musa DA, Salihu IM, Kawu AA, et al.
Seroprevalence of SARS-CoV-2 in Niger State: A Pilot Cross Sectional Study. MedRxiv.
2021:2020.08. 04.20168112.

471 20. Okpala OV, Dim CC, Ugwu CI, Onyemaechi S, Uchebo O, Chukwulobelu U, et al.

472 Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East,

473 Nigeria. Int J Infect Dis. 2021;110:171-8.

474 21. Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A, et al. Dynamics

of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective

476 study. Lancet Reg Health Eur. 2021;10:100208.

477 22. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune
478 Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med.
479 2021;385(24):e84.

Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al.
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet.
2021;398(10298):385-7.

483 24. Jiang HW, Li Y, Zhang HN, Wang W, Yang X, Qi H, et al. SARS-CoV-2 proteome
484 microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat
485 Commun. 2020;11(1):3581.

486 25. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic
487 Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016;24(6):490488 502.

Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al.
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not
associated with protection. Cell. 2021;184(7):1858-64 e10.

492 27. Maganga GD, Pinto A, Mombo IM, Madjitobaye M, Mbeang Beyeme AM,
493 Boundenga L, et al. Genetic diversity and ecology of coronaviruses hosted by cave494 dwelling bats in Gabon. Sci Rep. 2020;10(1):7314.

495 28. Lacroix A, Vidal N, Keita AK, Thaurignac G, Esteban A, De Nys H, et al. Wide
496 Diversity of Coronaviruses in Frugivorous and Insectivorous Bat Species: A Pilot Study in
497 Guinea, West Africa. Viruses. 2020;12(8).

498 29. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell.
499 2021;184(4):861-80.

500	30. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et
501	al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19
502	(AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270-8.
503	
504	Acknowledgments:
505	
506	We thank the many healthcare workers at Lagos University Teaching Hospital
507	that participated in this study. We also acknowledge the collaboration with the Lagos
508	State COVID-19 Taskforce in the evaluation of COVID-19 vaccine immunity. This study
509	was funded by Harvard University's Motsepe Presidential Research Accelerator Fund
510	for Africa.
511	
512	Author Contributions:
513	
514	Conceptualization: SA, BBH, PJK. Methodology: SA, BBH, BC, SO, AO, FO, SJO, IEA,
515	AN, DJH, CAC, PJK. Validation: SA, BBH, BC, SO, AO, FO, SJO, IEA, AN, DJH, CAC,
516	PJK. Formal Analysis: SA, BBH, BC, AO, DJH, CAC, PJK. Data Curation: SA, BBH, BC,
517	SO, AO, FO, SJO, IEA, AN, DJH, CAC, PJK. Writing – Original Draft Preparation: BBH.
518	Writing – Review & Editing: SA, BBH, BC, SO, AO, FO, SJO, IEA, AN, DJH, CAC, PJK.
519	Visualization: BBH, BC, CAC, PJK. Supervision: SA, AO, PJK. Funding Acquisition: PJK.
520	
521	Data Availability Statement:

523	All data produced in the present study are available upon reasonable request to
524	the corresponding author.
525	
526	Declaration of Interests:
527	BBH is a co-founder of Mir Biosciences, Inc., a company that develops T cell-
528	based diagnostics/vaccines for infections, cancer, and autoimmunity.
529	
530	
531	
532	
533	
534	
535	
536	
537	
538	
539	
540	
541	
542	
543	
544	
545	



Fig. 1. T cell responses to SARS-CoV-2 nucleocapsid (N) in healthcare workers
(HCWs). Whole blood samples were stimulated with SARS-CoV-2 N, then supernatants
were processed via an IFN-γ enzyme-linked immunosorbent assay for healthcare workers
who had antibodies to A) SARS-CoV-2 S+N, B) N-only, or C) were seronegative.
Responses are expressed as an arbitrary unit (IFN-γ signal) based on an OD<sub>405</sub>
measurement. Dashed line, assay cutoff.





Fig. 2. Evolution and boosting of SARS-CoV-2 spike (S) in individuals in the general 567 568 population post-vaccination. Sera sequentially collected from vaccine recipients in the 569 general population were subjected to Western blot analysis. The post-vaccination 570 evolution of SARS-CoV-2 S antibodies for each individual with baseline antibodies to A) 571 SARS-CoV-2 S+N, B) S-only, C) N-only, or D) who were seronegative (red lines represent 572 individuals who never developed S antibodies even after two vaccine rounds) determined 573 by image analysis where the S antibody signal was calculated and plotted as a % of 574 control. The x-axis corresponds to number of days post-vaccination. The y-axis 575 corresponds to background subtracted SARS-CoV-2 S signal normalized to the control 576 line for each Western blot. Dashed line, cutoff. E) The evolution of SARS-CoV-2 S 577 antibodies was determined by image analysis where the S antibody signals were

578	calculated and plotted as the mean S signal by time period for each baseline antibody
579	profile group. Dashed line, cutoff. F) Representative image of Western blots for groups of
580	individuals.
581	
582	
583	
584	
585	
586	
587	
588	
589	
590	
591	
592	
593	
594	
595	
596	
597	
598	
599	
600	



604	Fig. 3. Boosting of SARS-CoV-2 spike (S) in individuals in the general population
605	post-vaccination. Sera sequentially collected from individuals in the general population
606	were subjected to Western blot analysis. The level of antibody boosting was determined
607	by subtracting the mean SARS-CoV-2 S antibody signal between baseline and 7-days
608	post-vaccination, 7- and 14-days post-vaccination, and 14- and 84-days post-vaccination.
609	The S signals from each time period were then summed and plotted as a $\%$ of total in a
610	stacked format.
611	
612	
613	
614	
615	
616	
617	







Fig. 4. T cell responses to SARS-CoV-2 nucleocapsid (N) 7-days post-vaccination in individuals in the general population. Whole blood samples were stimulated with SARS-CoV-2 N, then supernatants were processed via an IFN-y enzyme-linked immunosorbent assay for individuals in the general population who had antibodies to A) SARS-CoV-2 S+N, B) N-only, or C) were seronegative. Responses are expressed as an arbitrary unit (IFN-y signal) based on an OD<sub>405</sub> measurement. Dashed line, assay cutoff. 

- 635
- 636 Tables:
- 637
- 638 Table 1. SARS-CoV-2 antibody seroprevalence among healthcare workers and the
- 639 general population.
- 640

		Antibody Seroprevalence at Baseline			
Cohort	Number	SARS-CoV-2: S+N Number Positive (%)	SARS-CoV-2: S-only Number Positive (%)	SARS-CoV-2: N-only Number Positive (%)	Seronegative Number Positive (%)
Healthcare Workers					
COVID-19 convalescent	40	38 (95.0)	2 (5.0)	-	-
No history of COVID-19	94	55 (58.5)	1 (1.1)	14 (14.9)	24 (25.5)
Overall	134	93 (69.4)	3 (2.2)	14 (10.4)	24 (17.9)
General Population – Vaccine Recipients					
Agbowa	24	15 (62.5)	1 (4.2)	5 (20.8)	3 (12.5)
Amuwo	23	8 (34.8)	1 (4.4)	5 (21.7)	9 (39.1)
lkorodu	24	16 (66.7)	-	4 (16.7)	4 (16.7)
Iwaya	22	9 (40.9)	1 (4.6)	4 (18.2)	8 (36.4)
Oshodi	22	12 (54.6)	-	5 (22.7)	5 (22.7)
All sites	115	60 (52.2)	3 (2.6)	23 (20.0)	29 (25.2)

641

642

643

644 Table 2. Performance of T cell IFN-γ against SARS-CoV-2 N in control groups.

645

Statistic	Value	95% Confidence Intervals
Sensitivity	87.50% (14/16)	61.65% to 98.45%
Specificity	92.31% (24/26)	74.87% to 99.05%
Positive Predictive Value	87.50%	64.60% to 96.41%
Negative Predictive Value	93.10%	76.56% to 97.78%